Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus

NCT06148649 on ClinicalTrials.gov · last registry update 2025-04-29

An unusually large phase 2: 234 participants, more than double the 110 typical for the stage. The sponsor logged completion for 27 February 2025. Primary outcome, as filed: Change from baseline of HbA1c at week 12. dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: dulaglutide
Trulicity
Sponsor: Dongguan HEC Biopharmaceutical R&D Co., Ltd.
Sponsor type: Industry
Enrollment: 234
Started: 2023-12-10
Primary completion: 2025-02-27 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change from baseline of HbA1c at week 12

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.